Example of Neurology and Therapy format
Recent searches

Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format Example of Neurology and Therapy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Neurology and Therapy — Template for authors

Publisher: Springer
Categories Rank Trend in last 3 yrs
Neurology (clinical) #75 of 343 up up by 79 ranks
Neurology #45 of 156 up up by 39 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 128 Published Papers | 744 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 05/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

SAGE

Quality:  
High
CiteRatio: 9.5
SJR: 1.729
SNIP: 1.739
open access Open Access

SAGE

Quality:  
High
CiteRatio: 7.3
SJR: 1.684
SNIP: 1.763
open access Open Access
recommended Recommended

SAGE

Quality:  
High
CiteRatio: 6.8
SJR: 1.651
SNIP: 1.671
open access Open Access

SAGE

Quality:  
High
CiteRatio: 4.3
SJR: 1.395
SNIP: 2.063

Journal Performance & Insights

CiteRatio

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

A measure of average citations received per peer-reviewed paper published in the journal.

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

5.8

14% from 2019

CiteRatio for Neurology and Therapy from 2016 - 2020
Year Value
2020 5.8
2019 5.1
2018 4.7
2017 3.3
2016 1.7
graph view Graph view
table view Table view

1.296

14% from 2019

SJR for Neurology and Therapy from 2016 - 2020
Year Value
2020 1.296
2019 1.135
2018 1.315
2017 0.917
2016 0.446
graph view Graph view
table view Table view

1.499

17% from 2019

SNIP for Neurology and Therapy from 2016 - 2020
Year Value
2020 1.499
2019 1.28
2018 0.974
2017 1.121
2016 0.514
graph view Graph view
table view Table view

insights Insights

  • CiteRatio of this journal has increased by 14% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

insights Insights

  • SJR of this journal has increased by 14% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 17% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Neurology and Therapy

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Springer

Neurology and Therapy

Approved by publishing and review experts on SciSpace, this template is built as per for Neurology and Therapy formatting guidelines as mentioned in Springer author instructions. The current version was created on 05 Jul 2020 and has been used by 766 authors to write and format their manuscripts to this journal.

Clinical Neurology

Medicine

i
Last updated on
05 Jul 2020
i
ISSN
2193-6536
i
Open Access
No
i
Sherpa RoMEO Archiving Policy
White faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
SPBASIC
i
Citation Type
Author Year
(Blonder et al, 1982)
i
Bibliography Example
Beenakker CWJ (2006) Specular andreev reflection in graphene. Phys Rev Lett 97(6):067,007, URL 10.1103/PhysRevLett.97.067007

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1007/S40120-017-0086-4
Vitamin D and Multiple Sclerosis: A Comprehensive Review
Martina B. Sintzel, Mark Rametta1, Anthony T. Reder2
01 Jun 2018 - Neurology and Therapy

Abstract:

Numerous observational studies have suggested that there is a correlation between the level of serum vitamin D and MS risk and disease activity. To explore this hypothesis, a literature search of large, prospective, observation studies, epidemiological studies, and studies using new approaches such as Mendelian randomization ... Numerous observational studies have suggested that there is a correlation between the level of serum vitamin D and MS risk and disease activity. To explore this hypothesis, a literature search of large, prospective, observation studies, epidemiological studies, and studies using new approaches such as Mendelian randomization was conducted. Available data and ongoing research included in this review suggest that the level of serum vitamin D affects the risk of developing MS and also modifies disease activity in MS patients. Newer Mendelian randomization analyses suggest there is a causal relationship between low vitamin D level and the risk of MS. Post-hoc evaluations from two phase 3 studies, BENEFIT and BEYOND, support the findings of observational trials. Study limitations identified in this review recognize the need for larger controlled clinical trials to establish vitamin D supplementation as the standard of care for MS patients. Though there is increasing evidence indicating that lower vitamin D levels are associated with increased risk of MS and with greater clinical and brain MRI activity in established MS, the impact of vitamin D supplementation on MS activity remains inadequately investigated. read more read less

Topics:

Vitamin D and neurology (58%)58% related to the paper, Mendelian randomization (56%)56% related to the paper
View PDF
222 Citations
open accessOpen access Journal Article DOI: 10.1007/S40120-017-0073-9
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Kaj Blennow1
01 Jul 2017 - Neurology and Therapy

Abstract:

A set of core cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) includes total tau (T-tau), phosphorylated tau (P-tau) and β-amyloid 42 (Aβ42). These biomarkers reflect some of the key aspects of AD pathophysiology, including neuronal degeneration, tau phosphorylation with tangle formation, and Aβ aggregation ... A set of core cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) includes total tau (T-tau), phosphorylated tau (P-tau) and β-amyloid 42 (Aβ42). These biomarkers reflect some of the key aspects of AD pathophysiology, including neuronal degeneration, tau phosphorylation with tangle formation, and Aβ aggregation with deposition of the peptide into plaques. The core AD CSF biomarkers have been validated clinically in numerous studies, and found to have a very high diagnostic performance to identify AD, both in the dementia and in the mild cognitive impairment stages of the disease. CSF Aβ42 has also been found to show very high concordance with amyloid PET to identify brain amyloid deposition. The synaptic protein neurogranin is a novel candidate CSF biomarker for AD and prodromal AD. High CSF neurogranin predicts future cognitive decline and seems to be more specific for AD than, for example, T-tau. Importantly, technical developments have given ultrasensitive measurement techniques that allow measurement of brain-specific proteins such as tau and neurofilament light (NFL) in blood samples. Both plasma tau and NFL are increased in AD, and a recent study showed that plasma NFL has a diagnostic performance comparable to the core AD CSF biomarkers, and predicted future cognitive decline. Future large longitudinal clinical studies are warranted to determine the potential for plasma tau and NFL to serve as first-in-line screening tools for neurodegeneration in primary care. read more read less

Topics:

Tau protein (56%)56% related to the paper, Cognitive decline (54%)54% related to the paper
View PDF
204 Citations
open accessOpen access Journal Article DOI: 10.1007/S40120-016-0040-X
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
19 Feb 2016 - Neurology and Therapy

Abstract:

Transthyretin (TTR) transports the retinol-binding protein-vitamin A complex and is a minor transporter of thyroxine in blood. Its tetrameric structure undergoes rate-limiting dissociation and monomer misfolding, enabling TTR to aggregate or to become amyloidogenic. Mutations in the TTR gene generally destabilize the tetramer... Transthyretin (TTR) transports the retinol-binding protein-vitamin A complex and is a minor transporter of thyroxine in blood. Its tetrameric structure undergoes rate-limiting dissociation and monomer misfolding, enabling TTR to aggregate or to become amyloidogenic. Mutations in the TTR gene generally destabilize the tetramer and/or accelerate tetramer dissociation, promoting amyloidogenesis. TTR-related amyloidoses are rare, fatal, protein-misfolding disorders, characterized by formation of soluble aggregates of variable structure and tissue deposition of amyloid. The TTR amyloidoses present with a spectrum of manifestations, encompassing progressive neuropathy and/or cardiomyopathy. Until recently, the only accepted treatment to halt progression of hereditary TTR amyloidosis was liver transplantation, which replaces the hepatic source of mutant TTR with the less amyloidogenic wild-type TTR. Tafamidis meglumine is a rationally designed, non-NSAID benzoxazole derivative that binds with high affinity and selectivity to TTR and kinetically stabilizes the tetramer, slowing monomer formation, misfolding, and amyloidogenesis. Tafamidis is the first pharmacotherapy approved to slow the progression of peripheral neurologic impairment in TTR familial amyloid polyneuropathy. Here we describe the mechanism of action of tafamidis and review the clinical data, demonstrating that tafamidis treatment slows neurologic deterioration and preserves nutritional status, as well as quality of life in patients with early-stage Val30Met amyloidosis. read more read less

Topics:

Tafamidis Meglumine (80%)80% related to the paper, Familial amyloid cardiomyopathy (73%)73% related to the paper, Tafamidis (65%)65% related to the paper, Transthyretin (59%)59% related to the paper, Amyloidosis (51%)51% related to the paper
View PDF
119 Citations
open accessOpen access Journal Article DOI: 10.1007/S40120-014-0020-Y
Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis.
Bernd C. Kieseier1, Myriam Benamor
20 Nov 2014 - Neurology and Therapy

Abstract:

Introduction Teriflunomide, indicated for the treatment of relapsing–remitting multiple sclerosis, is contraindicated in pregnancy based on signs of developmental toxicity in the offspring of rats and rabbits; developmental toxicity has also been observed in preclinical studies of other disease-modifying therapies. Despite t... Introduction Teriflunomide, indicated for the treatment of relapsing–remitting multiple sclerosis, is contraindicated in pregnancy based on signs of developmental toxicity in the offspring of rats and rabbits; developmental toxicity has also been observed in preclinical studies of other disease-modifying therapies. Despite the requirement to use reliable contraception in clinical trials evaluating the safety and efficacy of teriflunomide, a number of pregnancies have been reported. This work reports pregnancy outcomes in teriflunomide clinical trials. read more read less

Topics:

Teriflunomide (76%)76% related to the paper, Pregnancy (52%)52% related to the paper
View PDF
97 Citations
open accessOpen access Journal Article DOI: 10.1007/S40120-019-00160-9
Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations.
Brian Barry1, April Erwin, Jessica Stevens1, Carlo Tornatore1
01 Nov 2019 - Neurology and Therapy

Abstract:

Because the treatment of multiple sclerosis (MS) may span decades, the need often arises to make changes to the treatment plan in order to accommodate changing circumstances. Switching drugs, or the discontinuation of immunomodulatory agents altogether, may leave patients vulnerable to relapse or disease progression. In some ... Because the treatment of multiple sclerosis (MS) may span decades, the need often arises to make changes to the treatment plan in order to accommodate changing circumstances. Switching drugs, or the discontinuation of immunomodulatory agents altogether, may leave patients vulnerable to relapse or disease progression. In some cases, severe MS disease activity is noted clinically and on MRI after treatment withdrawal. When this disease activity is disproportionate to the pattern observed prior to treatment initiation, patients are said to have experienced rebound. Of the US Food and Drug Administration (FDA)-approved agents to treat MS, the drugs most commonly implicated in rebound are natalizumab and fingolimod. In this review based on the reported cases and data from clinical trials, we characterize disease rebound after fingolimod cessation. We also outline fingolimod rebound management considerations, summarizing what evidence is available to help clinicians mitigate the risk of rebound, switch therapies, and treat rebound events when they occur. The commonly encountered situation of fingolimod discontinuation prior to pregnancy is also discussed. read more read less

Topics:

Discontinuation (59%)59% related to the paper, Fingolimod (59%)59% related to the paper
View PDF
91 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Neurology and Therapy.

It automatically formats your research paper to Springer formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Neurology and Therapy format uses SPBASIC citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Neurology and Therapy in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Neurology and Therapy guidelines and auto format it.

2. Do you follow the Neurology and Therapy guidelines?

Yes, the template is compliant with the Neurology and Therapy guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Neurology and Therapy?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Neurology and Therapy citation style.

4. Can I use the Neurology and Therapy templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Neurology and Therapy.

5. Can I use a manuscript in Neurology and Therapy that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Neurology and Therapy that you can download at the end.

6. How long does it usually take you to format my papers in Neurology and Therapy?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Neurology and Therapy.

7. Where can I find the template for the Neurology and Therapy?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Neurology and Therapy's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Neurology and Therapy's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Neurology and Therapy an online tool or is there a desktop version?

SciSpace's Neurology and Therapy is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Neurology and Therapy?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Neurology and Therapy?”

11. What is the output that I would get after using Neurology and Therapy?

After writing your paper autoformatting in Neurology and Therapy, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Neurology and Therapy's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Neurology and Therapy?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Neurology and Therapy. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Neurology and Therapy?

The 5 most common citation types in order of usage for Neurology and Therapy are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Neurology and Therapy?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Neurology and Therapy's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Neurology and Therapy in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Neurology and Therapy Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Neurology and Therapy formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template